Using Decision Support to Promote Value Based Prescribing

Size: px
Start display at page:

Download "Using Decision Support to Promote Value Based Prescribing"

Transcription

1 Using Decision Support to Promote Value Based Prescribing Session 218, February 14, 2019 Adam Szerencsy, DO Medical Director, Ambulatory Informatics NYU Langone Health 1

2 Conflict of Interest Adam Szerencsy, DO Has no real or apparent conflicts of interest to report. 2

3 Agenda Why are we doing this? Prioritizing medication classes to target Interventions Results Limitations Factors impacting success 3

4 Learning Objectives Formulate a strategy for deploying decision support to influence medication prescribing Evaluate what types of metrics should be used to measure success Identify what factors contribute to provider acceptance of lower cost, therapeutic equivalent medications Define external processes that may limit the effectiveness of clinical decision support interventions Recognize barriers that may impact provider and patient adoption and limit cost savings 4

5 Background Value based payment programs continue to expand Healthcare organizations are consolidating to achieve efficiencies Healthcare technology is critical to measure and improve care 5

6 & NYU Langone IPA Over 400,000 attributed lives 2 billion in annual healthcare expenditures 3500 providers Approx. 75% of providers using our enterprise-wide EHR Value based arrangements with all major commercial and government funded insurers 6

7 & NYU Langone IPA Value Based Medicine Screening and Prevention Chronic Disease Management Appropriate Use Quality Cost Saving Bundled Payment Out of Network Spend Readmissions Reducing prescription drug costs Patient Satisfaction HCAHPS CGCAHPS 7

8 Can we use clinical decision support to guide clinicians to prescribe lower cost medications? 8

9 Prioritizing Therapeutic Classes to Target High per member per month (PMPM) med spend Alignment across plan formularies Little risk that a medication change will impact care Significant cost differential between high cost medication and alternative Strong evidence that therapeutic alternatives have similar efficacy Clinical leadership willing to support the initiative 9

10 *ULCER DRUGS/ANTISPASMODICS $ $ % *TETRACYCLINES $ $ % 10

11 Classes Individual Drugs Biguanides Tetracyclines PPIs Glumetza Fortamet Metformin MOD Oracea Doryx Morgidox Monodox Acticlate Solodyn Nexium Dexliant Aciphex Vimovo (PPI/Naproxen) 11

12 Drug Pricing Alphabet Soup Wholesale acquisition costs (WAC) Maximum allowable cost (MAC) Federal Upper limit Usual and customary (U&C) (FUL) Average manufacturer price (AMP) Estimated acquisition cost (EAC)

13 Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only...the pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. 13 Source: Lexicomp

14 Source: Goodrx.com

15 Source: Goodrx.com

16 Therapeutic Class Biguanide High Cost Agent Fortamet (Metformin ER) Average Wholesale Price (AWP)* Preferred Alternative Lowest Retail Price/Month* Price Differential/ Month $1260 Metformin ER $18 $1242 Biguanide Glumetza (Metformin ER) $3300 Metformin ER $18 $3282 Biguanide Metformin ER MOD $3600 Metformin ER $18 $ *Source: Lexicomp

17 Therapeutic Class High Cost Agent Average Wholesale Price (AWP)* Preferred Alternative Lowest Retail Price/Month* Price Differential /Month Tetracycline Acticlate/Doryx (Doxycycline Hyclate) $953/$1315 Doxycycline Hyclate $18 $935/$1297 Tetracycline Tetracycline Tetracycline Oracea/Monodox (Doxycycline Monohydrate) Solodyn (Minocycline) Morgidox Kit (Doxycycline Hyclate) $609/$394 Doxycycline Monohydrate $13 $596/$381 $1219 Minocycline $20 $1999 $550 Doxycycline Hyclate $18 $532 *Source: Lexicomp

18 Therapeutic Class High Cost Agent Average Wholesale Price (AWP)* Preferred Alternative Lowest Retail Price/Month* Price Differential/ Month PPI Dexilant (Dexlansoprazole) $310 Omeprazole Lansoprazole Pantoprazole $11 $18 $13 ~$295 PPI Nexium (Esomeprazole) $288 Omeprazole Lansoprazole Pantoprazole $11 $18 $13 ~$273 PPI Aciphex Rabeprazole $529 Omeprazole Lansoprazole Pantoprazole $11 $18 $13 ~$514 PPI Combination Vimovo Naproxen- Esomeprazole $2473 Omeprazole Lansoprazole Pantoprazole $11 $18 $13 ~$2450 (+ Naproxen) ($8) *Source: Lexicomp

19 Interventions Preference List Modifications Standard extended release formulation ($) Modified release formulations ($$$$) 2019 Epic Systems Corporation. Used with permission. 19

20 Interventions Preference List Modifications Removed high cost agents from provider and facility preference lists 2019 Epic Systems Corporation. Used with permission. 20

21 Interventions Preference List Modifications and substituted them with lower cost alternatives Epic Systems Corporation. Used with permission.

22 Interventions Alternative Alerts Interruptive messages recommending lower cost alternatives to providers Design Principles 1. Substitute same medication whenever possible 2. Maintain similar dose and frequency 3. Simple message 4. Provide a reference for additional information 5. Mechanism for feedback 22

23 Interventions Alternative Alert Mapping High Cost Medication Doryx 100 mg tablets (Doxycycline Hyclate) Solodyn 45 mg daily tabs (Minocycline) Fortamet 500 mg daily (Metformin ER) Fortamet 1000 mg daily (Metformin ER) Dexilant 30 mg daily (Dexlansoprazole) Vimovo mg daily (Naproxen-Esomeprazole) Lower Cost Alternative Doxycycline Hyclate 100 mg capsules Minocylcine 50 mg capsules Metformin ER 500 mg daily Metformin ER mg daily Metformin ER 750 mg daily Lansoprazole 15 mg daily Pantoprazole 20 mg daily Lansoprazole 30 mg daily Pantoprazole 40 mg daily (No Naproxen) 23

24

25 Interventions Alternative Alerts Epic Systems Corporation. Used with permission.

26 Interventions Socialization and Education Approval at CIN Clinical Practice Committee Support from clinical chiefs within therapeutic areas Presentations at various committee meetings EHR end-user communication and newsletter announcements 26

27 Acceptance Rate Results Metformin Metformin Alternative Acceptance Rate (n=1437) 35% 32.9% 30% 25% 20% 15% 16.8% 18.5% 10% 9.4% 5% 0% Overall Primary Care Endocrine Other Specialties Provider Specialty 27

28 Results Metformin Metformin Acceptance Rate by Dose/Formulation 25.0% 21.3% 20.0% 15.0% 12.8% 10.0% 5.0% 0.0% Metformin 500 mg /750 mg ER -> Glumetza 1000 mg ER Metformin 500 mg ER -> Glumetza 500 mg ER 28

29 Acceptance Rate Results Tetracyclines Tetracylines Alternative Acceptance Rate (n=783) 50% 45% 43.4% 40% 35% 30% 25% 20% 16.5% 17.1% 15% 11.9% 10% 5% 0% Overall Derm Primary Care Other Specialties Provider Specialty 29

30 Results Tetracyclines Alternative Acceptance Rate by Dose/Formulation 80.0% 70.0% 68.8% 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% 1.7% Doxycycline 20 mg - > Oracea 40 mg Doxy 100 mg caps - > Adoxa 100 mg tabs 30

31 Acceptance Rate Results PPIs PPI Alternative Acceptance Rate (n=12,488) 20% 18% 16% 14% 12% 10% 8% 6% 4% 2% 10.1% 10.3% 10.4% 9.8% 0% Overall Primary Care GI Other Specialties Provider Specialty 31

32 Results PPIs Alternative Acceptance Rate by Dose/Formulation 35.0% 30.0% 30.8% 25.0% 20.0% 15.0% 10.0% 10.6% 5.0% 0.0% Omeprazole 20 mg -> Esomeprazole 20 mg Pantoprazole 40 mg -> Dexlanzoprazole 60 mg 0.6% Omeprazole 20 mg -> Vimovo (Naproxen/Esomeprazole) 32

33 Results REASONS FOR CONTINUING ORIGINAL MEDICATION Prior failure/intolerance of alternative medication 21% Dosing differences Unwilling to change/ Change not necessary Convenience Patient preference 55% Alternative medications not covered 6% Dosing regimen not appropriate 4% Other (Comments) 14% 33

34 Acceptance Rate Results Summary Over Time 18.0% Acceptance Rate By Month 16.0% 14.0% 12.0% 10.0% 8.0% 6.0% 4.0% 2.0% 0.0% Jan-18 Feb-18 Mar-18 Apr-18 May-18 Jun-18 Jul-18 Aug-18 Sep-18 34

35 Results Payer Data 2017 vs 2018 Baseline Period: 01/01/ /31/2017; Current Period: 01/01/ /30/2018; Claims Paid Through 09/30/2018 PMPM Paid Scripts/1,000 Unit Cost % Generic Baseline Current $ Trend % Trend Baseline Current % Trend Baseline Current % Trend Baseline Current *Biguanides** $2.37 $1.78 -$ % % $116 $ % 97.9% 98.5% *Tetracyclines* $0.84 $0.59 -$ % % $105 $ % 92.5% 95.0% *Proton Pump Inhibitors** $1.49 $1.19 -$ % % $62 $ % 88.6% 90.5% Naproxen-Esomeprazole $0.31 $0.53 $ % % $2,083 $2, % 0.0% 0.0% Decrease of $0.93 PMPM

36 PMPM Net Change Results Payer Data Net Change in PMPM Cost 2017 vs Jan-Jun 2018 (therapeutic classes combined) $1.00 $0.80 $0.60 $0.40 $0.20 $0.14 $0.15 $0.00 -$0.20 -$0.40 -$ $0.60 -$0.80 -$1.00 -$0.77 High Cost Meds Low Cost Meds Unit Cost: High Cost Meds Unit Cost: Low Cost Meds= -$0.71 Overall Net Change PMPM Source: Anthem Commercial Monthly

37 Limitations Disparate claims data from payers and member roster changes make it challenging to calculate total savings and definitively attribute them to our interventions Inability to intervene for DAW brand medications Not all providers using enterprise-wide EHR Inability to filter alerts for just our attributed patients 37

38 Looking Ahead 2019 Epic Systems Corporation. Used with permission. 38

39 External Influencers 39

40 Prescription Drug Market Once daily dosing Combined meds Prepackaged kits Drug delivery mechanisms Convenience Cost Rx plan design Formularies Tiered Co-payments Prescriber EHR Efficacy Better adherence Patient

41 Warehouse Store Convenience Cost Sig: 0.65 oz po daily x 28 days Disp: 18.2 oz $12.99/18 oz - $4.00 Rebate $8.99/18 oz Consumer $5.99/12 oz $9.00/18 oz December 21, 2017

42 Warehouse Store Morgidox Kit 100 mg capsules (#30) + Acuwash cleanser Convenience Cost $ $16.76 Prescriber EHR Patient Source: Goodrx.com December 21, 2017

43 Warehouse Store Morgidox Kit 100 mg capsules (#30) + Acuwash cleanser Convenience Cost $ $16.36 ~ $30 - $50 Co-payment Prescriber EHR Patient ~ $5 - $15 Co-payment Profits Missed savings December opportunity 21, 2017

44 44

45 Provider Influencers Favoring High Cost Meds VS Favoring Lower Cost Meds Patient preference Status quo bias Pharmaceutical drug promotion Health system education EHR Provider incentives 45

46 Conclusions CDS interventions for promoting lower cost alternative medications are effective Alternative medications with same dose/frequency correlate with higher rates of alternative acceptance Patient preference greatly impacts acceptance rates - ease of dosing regimen Many external factors, misaligned incentives and complex relationships within the prescription drug market pose significant challenges to achieving maximum benefit 46

47 Questions/Comments Special thanks! Lisa Anzisi, PharmD Jin Gwon David Ranson Osman Khalid Chrystal Johnson Contact: 47

DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL

DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. UNIFORM FORMULARY REVIEW PROCESS Under 10 United States Code

More information

Prescription Drugs North Carolina Policies. Carol Steckel, MPH Medicaid Director

Prescription Drugs North Carolina Policies. Carol Steckel, MPH Medicaid Director Prescription Drugs North Carolina Policies Carol Steckel, MPH Medicaid Director March 19, 2013 Pharmacy Services Optional service provided each year to about 1.5 million beneficiaries by 2,200 pharmacy

More information

The Infection Control Doctor and Clostridium difficile infection. Dr David R Jenkins University Hospitals of Leicester NHS Trust, England

The Infection Control Doctor and Clostridium difficile infection. Dr David R Jenkins University Hospitals of Leicester NHS Trust, England The Infection Control Doctor and Clostridium difficile infection Dr David R Jenkins University Hospitals of Leicester NHS Trust, England 250 200 150 100 50 0 Monthly cases of Clostridium difficile (UHL

More information

Proton Pump Inhibitors (PPIs) (Sherwood Employer Group)

Proton Pump Inhibitors (PPIs) (Sherwood Employer Group) Proton Pump Inhibitors (PPIs) (Sherwood Employer Group) BCBSKS will review Prior Authorization requests Prior Authorization Form: https://www.bcbsks.com/customerservice/forms/pdf/priorauth-6058ks-st-ippi.pdf

More information

Update to HMO Drug Formulary Tier Definitions. February 8, 2018

Update to HMO Drug Formulary Tier Definitions. February 8, 2018 Update to HMO Drug Formulary Tier Definitions February 8, 2018 Agenda 1 Overview of Current Drug Tiers 2 Proposed Drug Tiers for 2019 3 Impact to SFHSS and SFHSS Members 4 How the Drug Formulary Works

More information

MAXIMUM ALLOWABLE COST POLICY CHANGES DECEMBER 5, 2016 QUESTIONS AND ANSWERS

MAXIMUM ALLOWABLE COST POLICY CHANGES DECEMBER 5, 2016 QUESTIONS AND ANSWERS MAXIMUM ALLOWABLE COST POLICY CHANGES DECEMBER 5, 2016 QUESTIONS AND ANSWERS The November 22, 2016 Mid-Year Financial Report referred to changes to drug coverage under the Saskatchewan Drug Plan. What

More information

Proton Pump Inhibitors

Proton Pump Inhibitors Market DC Proton Pump Inhibitors Override(s) Prior Authorization Quantity Limit** Approval Duration Preferred PPI: No Prior Authorization required Preferred PPI quantity override: Lifetime Non-Preferred

More information

Measuring and Evaluating Indicators of Appropriate Prescribing in Older. Populations

Measuring and Evaluating Indicators of Appropriate Prescribing in Older. Populations HRB PhD Scholar Division of Population Health Sciences RCSI Measuring and Evaluating Indicators of Appropriate Prescribing in Older Cost-Effective Proton Pump Populations Potential Strategies for more

More information

Rpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives

Rpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives Esomeprazole 20mg Name, Restriction, Manner of esomeprazole 20 mg enteric tablet, 30 (8886Q) (029W) Gastric ulcer Peptic ulcer Treatment Phase: Initial treatment The therapy must be for initial treatment

More information

Proton Pump Inhibitors. Description

Proton Pump Inhibitors. Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.01 Subject: Proton Pump Inhibitors Page: 1 of 6 Last Review Date: June 24, 2015 Proton Pump Inhibitors

More information

Market Distortions from the 340B Drug Pricing Program

Market Distortions from the 340B Drug Pricing Program Market Distortions from the 340B Drug Pricing Program Adam J. Fein, Ph.D. www.drugchannels.net @DrugChannels The opinions and views expressed in this presentation are those of the author and may not reflect

More information

Zegerid Capsules 20 mg and 40 mg Zegerid Powder for Oral Suspension 20 mg and 40 mg

Zegerid Capsules 20 mg and 40 mg Zegerid Powder for Oral Suspension 20 mg and 40 mg Nasdaq: SNTS Safe Harbor This presentation may include forward-looking statements that are based on our management s beliefs and assumptions and on information currently available to our management. The

More information

Drug Class Monograph

Drug Class Monograph Drug Class Monograph Class: Proton Pump Inhibitors Drugs: Aciphex Sprinkle (rabeprazole), Dexilant (dexlansoprazole), Lansoprazole, Nexium (esomeprazole capsule, esomeprazole granules), Omeprazole, Pantoprazole,

More information

Proton Pump Inhibitors. Description. Section: Prescription Drugs Effective Date: July 1, 2014

Proton Pump Inhibitors. Description. Section: Prescription Drugs Effective Date: July 1, 2014 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.09.01 Subject: Proton Pump Inhibitors Page: 1 of 7 Last Review Date: June 12, 2014 Proton Pump Inhibitors

More information

WELLPOINT RESPONDS TO ANCO s COMMENTS

WELLPOINT RESPONDS TO ANCO s COMMENTS WELLPOINT RESPONDS TO ANCO s COMMENTS Thank you again for taking the time to meet with us to learn about Anthem s Cancer Care Quality Program and the Wellpoint Cancer Treatment Pathways as well as your

More information

Omeprazole 10mg. Name, Restriction, Manner of administration and form OMEPRAZOLE omeprazole 10 mg enteric tablet, 30 (8332M) Max. Qty.

Omeprazole 10mg. Name, Restriction, Manner of administration and form OMEPRAZOLE omeprazole 10 mg enteric tablet, 30 (8332M) Max. Qty. Omeprazole 10mg Name, Restriction, Manner of administration and form omeprazole 10 mg enteric tablet, 30 (8332M) Gastro-oesophageal reflux disease Name, Restriction, Manner of administration and form omeprazole

More information

An Information Service of the Division of Medical Assistance. North Carolina Medicaid Pharmacy Newsletter. Number 249 December In This Issue...

An Information Service of the Division of Medical Assistance. North Carolina Medicaid Pharmacy Newsletter. Number 249 December In This Issue... An Information Service of the North Carolina Medicaid Pharmacy Newsletter Number 249 In This Issue... Pharmacy Pricing Changes Price Increase on Six Roche Accu-Check Products Effective Feb. 1, 2016 72-hour

More information

Information for Vermont Prescribers of Prescription Drugs Long Form

Information for Vermont Prescribers of Prescription Drugs Long Form Information for Vermont Prescribers of Prescription Drugs Long Form Pylera (bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride) Capsules The prices listed below are Average Wholesale

More information

Medication trends shaping workers compensation. A 2018 update of the prevailing industry influences impacting pharmacy outcomes

Medication trends shaping workers compensation. A 2018 update of the prevailing industry influences impacting pharmacy outcomes Medication trends shaping workers compensation A 2018 update of the prevailing industry influences impacting pharmacy outcomes This page intentionally left blank Trends impacting workers compensation pharmacy

More information

II. Angiotensin Receptor Blockers (ARBs) Drug Class Review

II. Angiotensin Receptor Blockers (ARBs) Drug Class Review DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE DOD BENEFICIARY ADVISORY PANEL I. Uniform Formulary Review Process Under 10 U.S.C. 1074g, as implemented by 32 C.F.R. 199.21,

More information

Spring Understanding the potential of generic substitution

Spring Understanding the potential of generic substitution Spring 2014 Understanding the potential of generic substitution Understanding the potential of generic substitution Generic pricing reforms and the availability of generics for blockbuster drugs coming

More information

Colorectal Cancer- QI process and clinic success: A Case Study at Atascosa Health Center

Colorectal Cancer- QI process and clinic success: A Case Study at Atascosa Health Center Colorectal Cancer- QI process and clinic success: A Case Study at Atascosa Health Center Kaela Momtselidze Health Systems Manager Primary Care Systems American Cancer Society Sheri Frank Director of Corporate

More information

IMPACT OF DRUG REBATES ON YOUR PARTICIPANTS AND YOUR PLAN RISK PROFILE Indiana Health and Wellness Summit

IMPACT OF DRUG REBATES ON YOUR PARTICIPANTS AND YOUR PLAN RISK PROFILE Indiana Health and Wellness Summit IMPACT OF DRUG REBATES ON YOUR PARTICIPANTS AND YOUR PLAN RISK PROFILE 2018 Indiana Health and Wellness Summit National Diabetes Volunteer Leadership Council Who We Are Patient advocacy organization committed

More information

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

Pharmacy Coverage Guidelines are subject to change as new information becomes available. PROTON PUMP INHIBITORS, NON-PREFERRED FORMS: ACIPHEX (rabeprazole sodium EC) oral tablet ACIPHEX SPRINKLE (rabeprazole sodium DR) oral capsule ESOMEPRAZOLE STRONTIUM (esomeprazole strontium DR) oral capsule

More information

Pharmacy Trends and Management Opportunities. Kerry Bendel, R.Ph. Director of Pharmacy Medica

Pharmacy Trends and Management Opportunities. Kerry Bendel, R.Ph. Director of Pharmacy Medica Pharmacy Trends and Management Opportunities Kerry Bendel, R.Ph. Director of Pharmacy Medica September 14, 20 1 Agenda Pharmacy Trend Experience Trend Drivers and Management Opportunities Call to Action

More information

Allergic reaction to doxycycline monohydrate

Allergic reaction to doxycycline monohydrate Allergic reaction to doxycycline monohydrate Vibramycin-D Dispersible Tablets 100mg - Summary of Product Characteristics (SmPC) by Pfizer Limited. 28-10-2016 Monodox ( doxycycline monohydrate ) is a tetracycline

More information

To Bundle or Not to Bundle?

To Bundle or Not to Bundle? To Bundle or Not to Bundle? Ronald Barkley, CCBD Group Mark Krasna, MD, Meridian Cancer Care Constantine Mantz, MD, 21 st Century Oncology Joseph O Hara, Horizon Blue Cross Lee Newcomer, MD, United Healthcare

More information

2017 Drug Trends Series

2017 Drug Trends Series 2017 Drug Trends Series Part 1 Evaluating the traditional view Retail and mail-order prescriptions Published April 2018 1 2017 Drug Trends Series Traditional View First Script A year of important progress

More information

Therapeutics Initiative A SHORT HISTORY

Therapeutics Initiative A SHORT HISTORY Therapeutics Initiative A SHORT HISTORY Therapeutics Initiative, 1994 (10 individuals) Mission: To provide physicians and pharmacists with up-to-date, evidence-based, practical information on prescription

More information

The Sustainability of Irish Pharmaceutical Expenditure. Valerie Walshe Ph.D. Economist

The Sustainability of Irish Pharmaceutical Expenditure. Valerie Walshe Ph.D. Economist The Sustainability of Irish Pharmaceutical Expenditure Valerie Walshe Ph.D. Economist valerie.walshe@hse.ie February 2015 Content Overview of Irish Health Services Community Drug Prescribing Trends Driving

More information

Rx Watchdog Report Trends in Manufacturer Prices of Generic Prescription Drugs Used by Medicare Beneficiaries 2003 to 2007

Rx Watchdog Report Trends in Manufacturer Prices of Generic Prescription Drugs Used by Medicare Beneficiaries 2003 to 2007 Rx Watchdog Report Trends in Manufacturer Prices of Generic Prescription Drugs Used by Medicare Beneficiaries 2003 to 2007 by David J. Gross AARP Outreach & Service Stephen W. Schondelmeyer PRIME Institute,

More information

Advances in Alignment, Measurement, and Performance MY 2017 Results Highlights

Advances in Alignment, Measurement, and Performance MY 2017 Results Highlights Advances in Alignment, Measurement, and Performance MY 2017 Results Highlights Align. Measure. Perform. (AMP) Programs Launched in 2003, VBP4P is a statewide performance improvement program and one of

More information

We see health care. differently. Comprehensive data Novel insights Transformative actions Lasting value

We see health care. differently. Comprehensive data Novel insights Transformative actions Lasting value We see health care differently Comprehensive data Novel insights Transformative actions Lasting value 24 Hours of Optum data: Creating a more complete health picture We capture: Largest EHR dataset 90

More information

High use of maintenance therapy after triple therapy regimes in Ireland

High use of maintenance therapy after triple therapy regimes in Ireland High use of maintenance therapy after triple therapy regimes in Ireland K Bennett, H O Connor, M Barry, C O Morain, J Feely Department of Pharmacology & Therapeutics Department of Gastroenterology Trinity

More information

What CEOs Don t Know about Health System Pharmacy

What CEOs Don t Know about Health System Pharmacy Pharmacy Executive Forum What CEOs Don t Know about Health System Pharmacy research technology consulting 2 Today s Presenters Rob Lazerow Managing Director The Advisory Board Company lazerowr@advisory.com

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Minocycline ER (Solodyn) and Microspheres (Arestin) Reference Number: CP.PMN.80 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan See Important Reminder

More information

Committee Approval Date: October 14, 2014 Next Review Date: October 2015

Committee Approval Date: October 14, 2014 Next Review Date: October 2015 Medication Policy Manual Topic: esomeprazole-containing medications: - Nexium - Vimovo - esomeprazole strontium Policy No: dru039 Date of Origin: May 2001 Committee Approval Date: October 14, 2014 Next

More information

In Australia, brand substitution of

In Australia, brand substitution of Pharmaceutical brand substitution in Australia are there multiple switches per prescription? Abstract Background: In Australia, brand substitution by pharmacists has been possible since 1994. There is

More information

Population Health Management Design: Optimizing the Outcomes for Special Populations 21th Annual ASHP Conference for Pharmacy Leaders

Population Health Management Design: Optimizing the Outcomes for Special Populations 21th Annual ASHP Conference for Pharmacy Leaders Learning objectives Define population health and its impact on pharmacy leaders. Population Health Management Design: Optimizing the Outcomes for Special Populations Meghan D. Swarthout, PharmD, MBA, BCPS

More information

Protection Keeping vaccines top-of-mind among competing priorities

Protection Keeping vaccines top-of-mind among competing priorities Prioritizing Protection Keeping vaccines top-of-mind among competing priorities By Suzanne Wolfe At Novant Health, continuous quality improvement is central to enhancing patient care across the organization

More information

Telemedicine: Connecting Behavioral Health and Medical Care

Telemedicine: Connecting Behavioral Health and Medical Care Telemedicine: Connecting Behavioral Health and Medical Care Lawrence S. Brown, Jr., MD, MPH, FASAM CEO, START Treatment & Recovery Centers Clinical Associate Professor of Medicine and Health Care and Policy

More information

THE GROWTH OF SPECIALTY PHARMACY

THE GROWTH OF SPECIALTY PHARMACY UnitedHealth Center for Health Reform & Modernization THE GROWTH OF SPECIALTY PHARMACY Current trends and future opportunities Issue Brief April 2014 Summary Innovative specialty drugs are providing important

More information

Statement Of. The National Association of Chain Drug Stores. For. U.S. Senate Committee on Finance. Hearing on:

Statement Of. The National Association of Chain Drug Stores. For. U.S. Senate Committee on Finance. Hearing on: Statement Of The National Association of Chain Drug Stores For U.S. Senate Committee on Finance Hearing on: 10:00 a.m. National Association of Chain Drug Stores (NACDS) 1776 Wilson Blvd., Suite 200 Arlington,

More information

Proton Pump Inhibitors Drug Class Prior Authorization Protocol

Proton Pump Inhibitors Drug Class Prior Authorization Protocol Proton Pump Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review

More information

Aligning Incentives and Designing Payment Systems to Promote Excellence in Cancer Care and Innovation

Aligning Incentives and Designing Payment Systems to Promote Excellence in Cancer Care and Innovation Aligning Incentives and Designing Payment Systems to Promote Excellence in Cancer Care and Innovation Deb Schrag MD MPH Dana Farber Cancer Institute Professor of Medicine Harvard Medical School Presentation,

More information

Health plans are charged with the difficult balance of

Health plans are charged with the difficult balance of RESEARCH Measuring Economic Impact of Applying Daily Average Consumption Limits Bridget M. Flavin, PharmD; Lynn M. Nishida, RPh; Sean H. Karbowicz, PharmD; Mark E. Renner; and Ruth J. Leonard, PharmD ABSTRACT

More information

Foundations in Community-Based Palliative Care Essential Elements for Success

Foundations in Community-Based Palliative Care Essential Elements for Success Foundations in Community-Based Palliative Care Essential Elements for Success Presented by Russell K Portenoy MD Foundations in Community-Based Palliative Care Essential Elements for Success Russell K

More information

Generics. Lead with. Prescription Step Therapy Program

Generics. Lead with. Prescription Step Therapy Program Lead with Generics Prescription Step Therapy Program WWW.BCBSLA.COM 04HQ3972 R11/10 Blue Cross and Blue Shield of Louisiana incorporated as Louisiana Health Service & Indemnity Company GENERIC DRUGS: A

More information

NCPA LTC Division Newsletter

NCPA LTC Division Newsletter March 2016 NCPA LTC Division Newsletter NCPA Offers FDA Additional Information on Repackaging Draft Guidance NCPA recently joined with the American Society of Consultant Pharmacists (ASCP) in a follow

More information

Prescription Switching and Reduced LDL-C Goal Attainment

Prescription Switching and Reduced LDL-C Goal Attainment Prescription Switching and Reduced LDL-C Goal Attainment JoAnne M. Foody, MD, FACC, FAHA Brigham and Women's Hospital, Boston, MA Disclosures Consultant for Merck and Pfizer Why Address Adherence? Increasing

More information

CHICAGO REGIONAL COUNCIL OF CARPENTERS WELFARE FUND RETIREE PRESCRIPTION DRUG BENEFITS October 2013

CHICAGO REGIONAL COUNCIL OF CARPENTERS WELFARE FUND RETIREE PRESCRIPTION DRUG BENEFITS October 2013 CHICAGO REGIONAL COUNCIL OF CARPENTERS WELFARE FUND RETIREE PRESCRIPTION DRUG BENEFITS October 2013 How to Use the Prescription Drug Program The Chicago Regional Council of Carpenters Welfare Fund has

More information

Michael J. Negrete, PharmD Chief Executive Officer

Michael J. Negrete, PharmD Chief Executive Officer Making the Most of Your Medications Michael J. Negrete, PharmD Chief Executive Officer 2 Drivers of Increasing Drug Spending Three main factors: Price Increases 24% Drug Mix 28% 3 Utilization 48% Aging

More information

2017 AlohaCare Advantage Plus Formulary (HMO SNP) Drugs with Step Therapy Requirements

2017 AlohaCare Advantage Plus Formulary (HMO SNP) Drugs with Step Therapy Requirements 2017 AlohaCare Advantage Plus Formulary (HMO SNP) Drugs with Step Therapy Requirements AlohaCare requires you to first try one drug to treat your medical condition before we will cover another drug for

More information

Difference between omeprazole and omeprazole delayed release

Difference between omeprazole and omeprazole delayed release Cari untuk: Cari Cari Difference between omeprazole and omeprazole delayed release 7-2-2018 Easy to read patient leaflet for Omeprazole Delayed-Release Capsules. Includes indications, proper use, special

More information

Drug Utilization Review & Cost Reduction Strategies. Esther Liu, PharmD, MSIA, CGP Clinical Pharmacist Outcome Resources

Drug Utilization Review & Cost Reduction Strategies. Esther Liu, PharmD, MSIA, CGP Clinical Pharmacist Outcome Resources Drug Utilization Review & Cost Reduction Strategies Esther Liu, PharmD, MSIA, CGP Clinical Pharmacist Outcome Resources Goals and Objectives Define Drug Utilization Reviews Interpret various performance

More information

Capitol Insights: A UC Center Sacramento Panel Discussion Soaring Drug Prices: Consumer and Clinician Perspectives and Policy Options

Capitol Insights: A UC Center Sacramento Panel Discussion Soaring Drug Prices: Consumer and Clinician Perspectives and Policy Options Capitol Insights: A UC Center Sacramento Panel Discussion Soaring Drug Prices: Consumer and Clinician Perspectives and Policy Options UCSF Center for Healthcare Value Philip R. Lee Institute for Health

More information

Evaluation of National Academic Detailing Service on Naloxone Kit Prescription Rates in the Veterans Health Administration

Evaluation of National Academic Detailing Service on Naloxone Kit Prescription Rates in the Veterans Health Administration Evaluation of National Academic Detailing Service on Naloxone Kit Prescription Rates in the Veterans Health Administration Melissa LD Christopher, PharmD National Director Academic Detailing Program Office

More information

Legislative & Regulatory Update Brad Young, RxPlus Government Affairs

Legislative & Regulatory Update Brad Young, RxPlus Government Affairs Legislative & Regulatory Update 2018 Brad Young, RxPlus Government Affairs Disclosures Brad Young reports no actual or potential conflicts of interest associated with this presentation. 2 Learning Objectives

More information

Statement Of. The National Association of Chain Drug Stores. For. U.S. House of Representatives Committee on the Budget.

Statement Of. The National Association of Chain Drug Stores. For. U.S. House of Representatives Committee on the Budget. Statement Of The National Association of Chain Drug Stores For U.S. House of Representatives Committee on the Budget Hearing on: 2:00 p.m. 210 Cannon House Office Building National Association of Chain

More information

Evaluation of Specialty Pharmacy in an Integrated Health-System

Evaluation of Specialty Pharmacy in an Integrated Health-System Evaluation of Specialty Pharmacy in an Integrated Health-System Emma Chermely, PharmD, BCACP Alyssa McCann, PharmD, BCACP *The presenters have no conflicts of interest to disclose. Objectives Introduce

More information

Texas Vendor Drug Program Specialty Drug List Process. February 2019

Texas Vendor Drug Program Specialty Drug List Process. February 2019 Texas Vendor Drug Program Specialty Drug List Process February 2019 Table of Contents Table of Contents...1 1 About the Specialty Drug List...2 1.1 Information for Pharmacies... 2 1.2 Information for Managed

More information

Innovation in Physician Payment and Organization for Cancer Care. Jennifer Malin, MD, PhD Medical Director, Oncology

Innovation in Physician Payment and Organization for Cancer Care. Jennifer Malin, MD, PhD Medical Director, Oncology Innovation in Physician Payment and Organization for Cancer Care Jennifer Malin, MD, PhD Medical Director, Oncology Current Oncology Care Model Unsustainable High Cost & Trend U.S. spending on cancer increased

More information

Design, Implementation, and First-year Results of a Value-based Formulary

Design, Implementation, and First-year Results of a Value-based Formulary Design, Implementation, and First-year Results of a Value-based Formulary Watkins JW, Sullivan SD, Yeung K, Ramsey SD, Garrison LP, Wong E, Murphy C, Danielson D, Veenstra DL, Vogeler C, Burke W, McGee

More information

Saving & Changing Lives: Ochsner s Opioid Stewardship Program

Saving & Changing Lives: Ochsner s Opioid Stewardship Program Saving & Changing Lives: Ochsner s Opioid Stewardship Program What Sparked our Interest How common opioid dependency was becoming How worrisome the morbidity and mortality in becoming in patient populations

More information

Session #206, March 8, 2018 Susan J. Kressly, MD, FAAP, Kressly Pediatrics Dr. Jacques Orces, D.O., Nicklaus Children s Hospital

Session #206, March 8, 2018 Susan J. Kressly, MD, FAAP, Kressly Pediatrics Dr. Jacques Orces, D.O., Nicklaus Children s Hospital Improving Preventative Care in Pediatrics through Health and Technology: A Davies Story Session #206, March 8, 2018 Susan J. Kressly, MD, FAAP, Kressly Pediatrics Dr. Jacques Orces, D.O., Nicklaus Children

More information

Doxycycline/Minocycline Step Therapy Criteria Program Summary

Doxycycline/Minocycline Step Therapy Criteria Program Summary This criteria applies to Commercial, NetResults F series and Health Insurance Marketplace formularies. OBJECTIVE The intent of the Doxycycline/Minocycline Step Therapy (ST) program is to encourage the

More information

KENT BISHOP M.D. ProMedica Chief Experience Officer President Women s Service Line

KENT BISHOP M.D. ProMedica Chief Experience Officer President Women s Service Line KENT BISHOP M.D. ProMedica Chief Experience Officer President Women s Service Line 1 WHEN A VISION TAKES SHAPE. 2 3 4 Modern Facilities Clinical Service Lines Quality/ Safety Mental Health Clinical Research

More information

Managed Care Trends in Statin Usage GARY R. BAZALO, MS, MBA

Managed Care Trends in Statin Usage GARY R. BAZALO, MS, MBA PHARMACY UTILIZATION Managed Care Trends in Statin Usage GARY R. BAZALO, MS, MBA ABSTRACT Purpose HMG-CoA reductase inhibitors ( statins ) have become the drug class of choice for the treatment of hyperlipidemia.

More information

Reducing COPD Exacerbation Readmissions in a Community-Based Teaching Hospital

Reducing COPD Exacerbation Readmissions in a Community-Based Teaching Hospital Reducing COPD Exacerbation Readmissions in a Community-Based Teaching Hospital Dawn Waddell, PharmD, BCPS Clinical Pharmacy Manager Lisa Kingdon, PharmD, BCPS Clinical Pharmacy Specialist Dawn Waddell

More information

STRENGTHENING THE COORDINATION, DELIVERY AND MONITORING OF HIV AND AIDS SERVICES IN MALAWI THROUGH FAITH-BASED INSTITUTIONS.

STRENGTHENING THE COORDINATION, DELIVERY AND MONITORING OF HIV AND AIDS SERVICES IN MALAWI THROUGH FAITH-BASED INSTITUTIONS. STRENGTHENING THE COORDINATION, DELIVERY AND MONITORING OF HIV AND AIDS SERVICES IN MALAWI THROUGH FAITH-BASED INSTITUTIONS. Acknowledgements This project was fully funded by Center For Disease Control

More information

Canadian Diabetes Association 2013

Canadian Diabetes Association 2013 Spring 2014 Canadian Diabetes Association 2013 clinical practice guidelines - Do claims data align to the guidelines? Canadian Diabetes Association 2013 clinical practice guidelines - Do claims data align

More information

Blood Pressure Management: A Journey in Quality Improvement Phil E. Yphantides, M.D.

Blood Pressure Management: A Journey in Quality Improvement Phil E. Yphantides, M.D. Blood Pressure Management: A Journey in Quality Improvement Phil E. Yphantides, M.D. Medical Director, Urgent Care Hypertension and Diabetes Physician Champion Sharp Rees-Stealy Medical Group San Diego,

More information

BRINTELLIX. Step Therapy Criteria HealthTeam Advantage Formulary ID: Version 6 Effective Date: 1/1/2016. PRODUCT(s) AFFECTED BRINTELLIX

BRINTELLIX. Step Therapy Criteria HealthTeam Advantage Formulary ID: Version 6 Effective Date: 1/1/2016. PRODUCT(s) AFFECTED BRINTELLIX BRINTELLIX BRINTELLIX Claim will pay automatically for brintellix if enrollee has a paid claim for at least a 1 days supply of any 2 generic formulary antidepressants in the past 365 days. Otherwise, brintellix

More information

COMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées

COMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées OPTIMAL THERAPY REPORT COMPUS Volume 1, Issue 6 March 2007 Gap Analysis Report for the Prescribing and Use of Proton Pump Inhibitors (PPIs) Supporting Informed Decisions À l appui des décisions éclairées

More information

Quality Metrics & Immunizations

Quality Metrics & Immunizations Optimizing Patients' Health by Improving the Quality of Medication Use Quality Metrics & Immunizations Hannah Fish, PharmD, CPHQ Discussion Objectives 1. Describe the types and distribution of quality

More information

UF Decision Report FY06-07 Beneficiary Advisory Panel 10 Jan 2008

UF Decision Report FY06-07 Beneficiary Advisory Panel 10 Jan 2008 UF Decision Report FY06-07 Beneficiary Advisory Panel 10 Jan 2008 Promoting high quality, cost effective drug therapy throughout the Military Health System UF Decisions, May 07 Class FY05 rank, total $

More information

Maryland Department of Health and Mental Hygiene 201 W. Preston Street Baltimore, Maryland 21201

Maryland Department of Health and Mental Hygiene 201 W. Preston Street Baltimore, Maryland 21201 STATE OF MARYLAND DHMH Maryland Department of Health and Mental Hygiene 201 W. Preston Street Baltimore, Maryland 21201 Martin O Malley, Governor Anthony G. Brown, Lt. Governor John M. Colmers, Secretary

More information

2018 Investor Presentation

2018 Investor Presentation 2018 Investor Presentation FORWARD LOOKING STATEMENT This presentation includes forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform

More information

How Mail-Servi. Prepared for

How Mail-Servi. Prepared for How Mail-Servi ice Pharmacies Will Save $46.6 Billion Over the Next Decade and the Cost of Proposed Restrictions Prepared for February 2012 Table of Contents I. Executive Summary... 3 Major Findings on

More information

Team-Based Decision Support in Diabetes Outcomes and Costs

Team-Based Decision Support in Diabetes Outcomes and Costs Team-Based Decision Support in Diabetes Outcomes and Costs Session 89, 8:30 a.m. February 13, 2019 Gary Ozanich, Ph.D. - College of Informatics, Northern Kentucky University 1 Conflict of Interest Gary

More information

PPIs: Good or Bad? 1. Basics of PPIs. Gastric Acid Basics. Outline. Gastric Acid Basics. Proton Pump Inhibitors (PPI)

PPIs: Good or Bad? 1. Basics of PPIs. Gastric Acid Basics. Outline. Gastric Acid Basics. Proton Pump Inhibitors (PPI) Outline Quick basics on Proton Pump Inhibitors (PPIs) PPIs: Good or Bad? What are potential risks of PPI therapy? How to approach your patients American Gastroenterology Association (AGA) recommendations

More information

FREQUENTLY ASKED QUESTIONS

FREQUENTLY ASKED QUESTIONS When it comes to your health, it s normal to have a lot of questions. Whether you ve got questions about when and where Nexium 24HR is available to purchase, or how Nexium 24HR works and should be taken,

More information

An Updated Approach to Colon Cancer Screening and Prevention

An Updated Approach to Colon Cancer Screening and Prevention An Updated Approach to Colon Cancer Screening and Prevention Kevin Liebovich, MD Director for Quality for Gastrointestinal diseases Advocate Condell Medical Center Colon Cancer Screening and Prevention

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Glumetza, Fortamet) Reference Number: CP.HNCA.72 Effective Date: 11.01.15 Last Review Date: 05.18 Line of Business: Commercial - HNCA Revision Log See Important Reminder at the end of

More information

Justifying New Oncology Pharmacist Positions

Justifying New Oncology Pharmacist Positions Faculty Disclosures Justifying New Oncology Pharmacist Positions I will not be discussing off-label uses of any medications I am on the speaker s bureau for Millenium Pharmaceuticals and am a paid consultant

More information

REIMBURSEMENT AND ITS IMPACT ON YOUR DIALYSIS PROGRAM Tony Messana Executive Director Renal Services St. Joseph Hospital - Orange

REIMBURSEMENT AND ITS IMPACT ON YOUR DIALYSIS PROGRAM Tony Messana Executive Director Renal Services St. Joseph Hospital - Orange REIMBURSEMENT AND ITS IMPACT ON YOUR DIALYSIS PROGRAM Tony Messana Executive Director Renal Services St. Joseph Hospital - Orange Agenda History of the Medicare ESRD Program Cost of Care for ESRD Patients

More information

Introduction. Summary A LOOK AT CAR-T THERAPIES MARCH 2018 LEUKEMIA AND LYMPHOMA CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY

Introduction. Summary A LOOK AT CAR-T THERAPIES MARCH 2018 LEUKEMIA AND LYMPHOMA CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY MARCH 2018 Introduction LEUKEMIA AND LYMPHOMA This review focuses on two types of B-cell cancers: childhood B-cell acute lymphoblastic leukemia (B-ALL), and aggressive B-cell non-hodgkin s lymphoma (NHL)

More information

You May Be at Risk. You are currently taking a proton-pump inhibitor (PPI): Dexlansoprazole (Dexilant ) Pantoprazole (Pantoloc, Panto IV )

You May Be at Risk. You are currently taking a proton-pump inhibitor (PPI): Dexlansoprazole (Dexilant ) Pantoprazole (Pantoloc, Panto IV ) You May Be at Risk. You are currently taking a proton-pump inhibitor (PPI): Dexlansoprazole (Dexilant ) Esomeprazole (Nexium ) Omeprazole (Losec, Olex ) Pantoprazole (Pantoloc, Panto IV ) Pantoprazole

More information

Policy Evaluation: Proton Pump Inhibitors (PPIs)

Policy Evaluation: Proton Pump Inhibitors (PPIs) Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Doxycycline/Minocycline Step Therapy Criteria Program Summary

Doxycycline/Minocycline Step Therapy Criteria Program Summary Doxycycline/Minocycline Step Therapy Criteria Program Summary Step therapy applies to Commercial and Health Insurance Marketplace formularies only. OBJECTIVE The intent of the Doxycycline/Minocycline Step

More information

Big Data & Predictive Analytics Case Studies: Applying data science to human data Big-Data.AI Summit

Big Data & Predictive Analytics Case Studies: Applying data science to human data Big-Data.AI Summit Big Data & Predictive Analytics Case Studies: Applying data science to human data 1.03.2018 Big-Data.AI Summit Dr. Arnim Jost, Commercial Director Technology Copyright 2017 IQVIA. All rights reserved.

More information

Unequal Treatment: Disparities in Access, Quality, and Care

Unequal Treatment: Disparities in Access, Quality, and Care Unequal Treatment: Disparities in Access, Quality, and Care Brian D. Smedley, Ph.D. National Collaborative for Health Equity www.nationalcollaborative.org Healthcare Disparities: Are We Making Progress?

More information

Class Update: Tetracyclines

Class Update: Tetracyclines Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Positive Living Conference

Positive Living Conference Positive Living Conference Ft. Walton Beach, Thomas Liberti Chief, Bureau of HIV/AIDS Department of Health March 11, 2011 Tallahassee, 1 The Epidemic in, 2010 60% White Population: 18.8 million (4 th 16%

More information

Institute of Quality Leadership AMGA

Institute of Quality Leadership AMGA Institute of Quality Leadership AMGA Ajay Sahajpal, MD Director Abdominal Transplant and Hepatobiliary Program Bradley Kruger, VP Operations ASLMC Laura Spurr, Director Clinical Transformation and Operations

More information

Published by the Pharmaceutical Services Division to provide information for British Columbia s health care providers

Published by the Pharmaceutical Services Division to provide information for British Columbia s health care providers Published by the Pharmaceutical Services Division to provide information for British Columbia s health care providers QuickLinks Keeping the Lines Clear... 1 Newsletter Notification Service... 1 Special

More information

Nasdaq: SNTS. January 11, 2010

Nasdaq: SNTS. January 11, 2010 Nasdaq: SNTS January 11, 2010 Safe Harbor This presentation may include forward-looking statements that are based on our management s beliefs and assumptions and on information currently available to our

More information

Carisoprodolol Quantity Limit Policy Impact Analysis

Carisoprodolol Quantity Limit Policy Impact Analysis Carisoprodolol Quantity Limit Policy Impact Analysis Carisoprodolol (Soma ) is a skeletal muscle relaxant that has deemed by many to have limited effectiveness for the treatment of acute musculoskeletal

More information

Palliative Care and Hospice in an Accountable Care Model. Key Strategies to a Successful Integrated Delivery System

Palliative Care and Hospice in an Accountable Care Model. Key Strategies to a Successful Integrated Delivery System Palliative Care and Hospice in an Accountable Care Model Key Strategies to a Successful Integrated Delivery System Monique Reese DNP, ARNP, FNP-C, ACHPN Lori Bishop RN, CHPN Objectives Describe the formation

More information